Apricus Biosciences Unternehmenskultur

Ms. Mary Naggs has been Vice President and General Counsel of Apricus Biosciences, Inc. since January 01, 2017 and served as Associate General Counsel. Since joining Apricus in 2011, Ms. Naggs has held various roles with increasing responsibility. In her new role, Ms. Naggs oversees all legal matters, including contracts, corporate governance, employment, financing transactions, compliance and intellectual property. Ms. Naggs graduated summa cum laude from Thomas Jefferson School of Law and she received her bachelor's degree in biochemistry and cell biology from Revelle College, University of California at San Diego. Ms. Naggs graduated summa cum laude from Thomas Jefferson School of Law and she received her bachelor's degree in biochemistry and cell biology from Revelle College, University of California at San Diego.

Ms. Kelly Deck has been Executive Director of Finance at Apricus Biosciences, Inc. since June 30, 2017. Ms. Deck joined the finance team of Apricus as Director of SEC Reporting in July 2013. Prior to Apricus, Ms. Deck held various roles in the accounting and finance departments for pharmaceutical and biotechnology companies, such as at Gen-Probe, Inc., which was acquired by Hologic, Inc. in August 2012, as well as La Jolla Pharmaceutical Company, Inc. and Cytori Therapeutics, Inc. Before transitioning to private industry, Ms. Deck began her career in public accounting for a local firm in Atlanta, Georgia. Ms. Deck holds a Bachelor of Business Administration in Accounting and a Master of Science in Accounting, both from the University of Cincinnati. She is an active licensed CPA in California.

Mr. Neil C. Morton has been Chief Business Officer and Senior Vice President of Apricus Biosciences, Inc., since April 8, 2016 and served as its Vice President of Business Development since March 20, 2014 until April 8, 2016. Mr. Morton has a successful track record in business development in specialty pharmaceuticals, serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. Prior to Auxilium Pharmaceuticals, he served in business development and marketing roles at King Pharmaceuticals, attaining the position of Senior Director of Commercial Development. Mr. Morton received his M.B.A. degree from the Babcock Graduate School of Management at Wake Forest University and his B.A. degree in biology from Bucknell University.